Alzheimer's Disease Trial, Recruiting NCT05887674 Sponsor: Ruijin Hospital Condition: Alzheimer's Disease
Back to Alzheimers Disease

Alzheimer's Disease Trial, Recruiting

NCT05887674
Recruiting Not Applicable

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • People aged between 60 and 90 years old
  • People who have been diagnosed with either mild cognitive impairment linked to Alzheimer's disease, or mild Alzheimer's disease, based on recognised international diagnostic guidelines (NIA-AA 2011 criteria)
  • People whose depression symptoms score 10 or below on a standard depression rating scale (the HAMD-17)
  • People whose neurological examination shows no significant or obvious signs of neurological problems
  • People who have completed at least primary school education (up to Grade 6) and are able to complete thinking and memory tests
  • People who are able to give their own informed consent to participate

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People whose memory or thinking difficulties are caused by something other than Alzheimer's disease, such as stroke-related brain changes, brain infections, Huntington's disease, Parkinson's disease, head injury, drug or alcohol effects, liver or lung disease affecting the brain, blood clots or tumours in the brain, thyroid or other hormone conditions, or vitamin deficiencies
  • People with a history of neurological conditions such as stroke, a condition affecting the optic nerve and spinal cord (optic myelitis), Parkinson's disease, or epilepsy
  • People with a history of psychiatric conditions such as schizophrenia, bipolar disorder, major depression, or delirium
  • People with serious or unstable heart, lung, liver, kidney, hormone system, or blood-related conditions, or those with a serious illness such as cancer with a poor outlook
  • People whose vision or hearing difficulties would significantly affect their ability to complete cognitive tests
  • People with a history of severe alcohol misuse or drug misuse in the past two years
  • People who have taken part in another clinical trial within the 30 days before their screening visit for this trial
  • People for whom MRI scanning is not medically safe (confirm with trial site)
  • People with specific dietary requirements, such as allergies to common foods or a medically required special diet
  • People who would not be able to attend follow-up appointments for at least 6 months, whether due to health reasons or plans to relocate

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 30 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 021-64370045

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Registry
ClinicalTrials.gov
Start date
11 May 2023
Est. completion
30 August 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Change from baseline global cognitive function at one year; Change from baseline memory at one year; Change from baseline visual spatial ability and visual memory at one year

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov